Release date: 2012-09-28
Using the high mutation of HIV, one can use it to create highly effective drug molecules.
Can HIV be transformed into a biotechnology tool that is good for human health? According to a research team at the French National Institute of Science (CNRS) "Architecture et Réactivité de l'ARN" laboratory, the answer is yes. Using HIV replication mechanisms, the researchers successfully screened for a specific variant protein. They added the protein together with the anticancer drug to the culture medium of the cancer cells, and as a result, only 1/300 of the normal dose was used to achieve the anticancer effect, which greatly improved the drug effect.
The research was published in the August 23, 2012 issue of PLoS Genetics. This finding is likely to take the lead in long-term therapeutic applications for cancer treatment and other conditions.
HIV is the chief culprits of AIDS. HIV is largely replicated by inserting its own genetic material into the genome of the host cell, using human cellular material. A striking feature of HIV is that it continually mutates and eventually produces multiple variant proteins during its continuous replication. This property allows HIV to adapt to complex and volatile environments, making antiviral drugs that have been developed into powerless.
At the Institute of Molecular and Cellular Biology (IBMC) at the University of Strasbourg, scientists at the Institute of RNA Structures and Reactions have developed a multiplication strategy using HIV to achieve therapeutic goals, especially treatment, by transforming the HIV virus. The idea of ​​cancer.
They first inserted into the genome of HIV a gene that is found in all human cells, the deoxycytidine kinase (dCK) gene, a protein that activates anticancer drugs. For many years, researchers have been looking for a more efficient form of deoxycytidine kinase. Through HIV replication and mutation, CNRS's research team has screened a "protein library" containing nearly 80 variants. They applied the variant protein to the tumor along with an anticancer drug and tested the ability of this combination to kill tumor cells. It was found that the modified deoxycytidine kinase was more effective in killing tumor cells in the culture medium than the normal (non-mutated) protein. After the anticancer drug is combined with this variant protein, the same effect can be achieved with only 1/300 of the normal dose. We know that as long as the dose of anticancer drugs can be reduced, the troubles caused by their toxic components can be alleviated, side effects can be reduced, and the most important thing is to improve the efficacy of anticancer drugs.
The ability to test these variant proteins directly on cells in the culture medium is a major advantage of this experimental technique. The next step in the experiment was to use a few years of preclinical (animal) studies of individual variant proteins. In addition, this experiment takes advantage of the deadly virus in the traditional sense and may lead to many other therapeutic applications.
Source: Global Science (huanqiukexue.com)
Marine Tourism Food,Shrimp Skin,Seaweed Snacks,Dried Shrimp
Zhoushan Fudan Tourism CO., LTD , https://www.fudanfood.com